Day: July 12, 2023

PETAH TIKVA, Israel and TYSONS CORNER, Va., July 12, 2023 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in Digital Intelligence (“DI”) solutions for the public and private sectors, today announced it will report its second-quarter 2023 financial results before market open on Tuesday, August 8, 2023.

Later that same morning, Cellebrite will host a live conference call and webcast to review the Company’s financial results for the first quarter of 2023 and discuss its full-year 2023 outlook. Pertinent details include:

In conjunction with the conference call and webcast, historical financial tables and supplemental data will be available on the quarterly results section of Company’s investor relations website at https://investors.cellebrite.com/financial-information/quarterly-results. A transcript of the call will be added to this page along with access to the replay of the call.

About Cellebrite
Cellebrite’s (NASDAQ: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more, visit us at www.cellebrite.com and https://investors.cellebrite.com.

Media
Victor Cooper
Sr. Director of Corporate Communications + Content Operations
Victor.cooper@cellebrite.com
+1 404.804.5910

Investor Relations
Andrew Kramer
Vice President, Investor Relations
investors@cellebrite.com
+1 973.206.7760

Caution Regarding Forward Looking Statements

This document includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “will,” “appear,” “approximate,” “foresee,” “might,” “possible,” “potential,” “believe,” “could,” “predict,” “should,” “could,” “continue,” “expect,” “estimate,” “may,” “plan,” “outlook,” “future” and “project” and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward looking statements include estimated financial information. Such forward looking statements with respect to revenues, earnings, performance, strategies, prospects, and other aspects of Cellebrite’s business are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: Cellebrite’s ability to keep pace with technological advances and evolving industry standards; Cellebrite’s material dependence on the acceptance of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite’s DI solutions; Cellebrite’s failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; uncertainties regarding the impact of macroeconomic and/or global conditions, including COVID-19 and military actions involving Russia and Ukraine; intense competition in all of Cellebrite’s markets; the inadvertent or deliberate misuse of Cellebrite’s solutions; political and reputational factors related to Cellebrite’s business or operations; risks relating to estimates of market opportunity and forecasts of market growth; Cellebrite’s ability to properly manage its growth; risks associated with Cellebrite’s credit facilities and liquidity; Cellebrite’s reliance on third-party suppliers for certain components, products, or services; challenges associated with large transactions and long sales cycle; risks that Cellebrite’s customers may fail to honor contractual or payment obligations; risks associated with a significant amount of Cellebrite’s business coming from government customers around the world; risks related to Cellebrite’s intellectual property; security vulnerabilities or defects, including cyber-attacks, information technology system breaches, failures or disruptions; the mishandling or perceived mishandling of sensitive or confidential information; the complex and changing regulatory environments relating to Cellebrite’s operations and solutions; the regulatory constraints to which we are subject; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite’s shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite’s significant international operations; risks associated with Cellebrite’s failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite’s existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite’s current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled “Risk Factors” in Cellebrite’s annual report on Form 20-F filed with the SEC on March 29, 2022,as amended on April 14, 2022 and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission (“SEC”), which are available free of charge at www.sec.gov. You are cautioned not to place undue reliance upon any forward looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

GlobeNewswire Distribution ID 8873303

Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster

SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE). Recursion also announced plans to accelerate development of its AI foundation models for biology and chemistry, which, in collaboration with NVIDIA, it intends to optimize and distribute to biotechnology companies using NVIDIA cloud services.

“Our collaboration with NVIDIA represents two best-in-class companies coming together to help solve one of the world’s most difficult challenges, drug discovery,” said Chris Gibson, Ph.D., Co-founder and CEO of Recursion. “With our powerful dataset and NVIDIA’s accelerated computing capabilities, we intend to create groundbreaking foundation models in biology and chemistry at a scale unlike anything that has ever been released in the biological space.”

Recursion plans to utilize its vast proprietary biological and chemical dataset, which exceeds 23 petabytes and 3 trillion searchable gene and compound relationships, to accelerate the training of foundation models on NVIDIA DGX Cloud for possible commercial license/release on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery. NVIDIA will also help optimize and scale Recursion foundation models leveraging the NVIDIA AI stack and NVIDIA’s full-stack computing expertise. BioNeMo was announced earlier this year as a cloud service for generative AI in drug discovery, offering tools to quickly customize and deploy domain-specific, state-of-the-art biomolecular models at-scale through cloud APIs. Recursion anticipates using this software to support its internal pipeline as well as its current and future partners.

“Generative AI is a revolutionary tool to discover new medicines and treatments,” said Jensen Huang, founder and CEO of NVIDIA. “We are delighted to collaborate with Recursion’s world-class team, which is doing pioneering work in digital biology and chemistry with NVIDIA DGX and NVIDIA AI software to accelerate the development of the world’s largest biomolecular generative AI models and speed drug discovery for biotech and pharmaceutical companies.”

Recursion, through its recent acquisition of Valence Discovery, aims to accelerate the development of new technologies to feed the biopharma industry, while simultaneously democratizing access to large-scale models that have maximum impact in drug discovery.

About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the acceleration and advancement of development of AI foundation models, as well as optimizing, licensing, and distributing such models; using BioNeMo software to support Recursion’s internal pipeline and well as Recursion’s current and future industry partners; Recursion accelerating development of new technologies through its Valence Discovery acquisition; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

GlobeNewswire Distribution ID 8872969

The positive verdict of the arbitration process initiated by a third party trying to block the deal

AMFRESH

Following the agreement between International Fruit Genetics LLC (IFG) and Special New Fruit Licensing Limited (SNFL), the consortium led by AMFRESH Group, as well as the Swedish fund EQT and the American fund Paine Schwartz Partners (PSP), for the purchase of the entire IFG business by SNFL, Jack Pandol initiated legal action to block the transaction.

MADRID, Spain, July 12, 2023 (GLOBE NEWSWIRE) — Following the agreement between International Fruit Genetics LLC (IFG) and Special New Fruit Licensing Limited (SNFL), the consortium led by AMFRESH Group, as well as the Swedish fund EQT and the American fund Paine Schwartz Partners (PSP), for the purchase of the entire IFG business by SNFL, Jack Pandol initiated legal action to block the transaction.

On July, 11th the arbitrator assigned to decide on the matter rejected all the claims made by Jack Pandol, allowing the transaction to proceed.

SNFL expects to close the transaction in the coming weeks.

As Alvaro Muñoz, AMFRESH CEO, points out, “our entire team and partners are proud to be able to move forward with the green light of the arbitration. This is the beginning of a breakthrough for the FRESH food sector and our greatest ambition is to foster the most innovative, natural, sustainable and healthy products to delight consumers globally. Our aim is to increase consumption and market size of fresh, healthy and affordable products globally”.

Additionally, Bluestone Food and Tech, Alvaro Muñoz’s family holding, closes an agreement to become the sole 100% equity partner of AMFRESH Group and acquire 100% of AMC Group. The deal has the full support of all the executive and non-executive board members of Bluestone and AMFRESH. It has also been supported by all the banking partners of the Business Group, as well as the partners in various investments that AMFRESH holds in Genetics and Technology (EQT and PSP). This will give AMFRESH total freedom to invest in the different agribusiness and agri-technology breakthroughs the group fully endorse.

AMFRESH, a group that in recent years has been in full expansion and involved in M&A activity, will follow its Strategic Plan with the objective of doubling its sales (currently €1.5 Billion in 2023) to reach €3 Billion in 2028 and tripling its EBITDA in the same timeframe.

Pablo Sánchez-Lozano, COO of AMFRESH Group, says “At AMFRESH we have been working on the integration of our supply chain with the aim of always adding value to our retail partners. Our focus is on offering innovative solutions that allow differentiation and are always based on technology. We have tools that cover the full cycle including genetics, agriculture, technology and sustainable practices; our degree of flexibility is unparalleled, and our customized models adapt to all clients, geographies and categories”.

AMFRESH is a leader in varietal genetic development for fresh food, with a solid global expansion based on a high value-added agriculture that is nature positive and sustainable and full integration of the food supply chain all the way to its retail partners. AMFRESH operates seamlessly by maintaining long-term agreements with its global retail partners and using an open-book policy.

The pillars of AMFRESH’s strategic growth are focused on 6 main areas distributed throughout the value chain:

• Become the preferred integrated partner of the top main retailers in the world by increasing its presence through new categories and offering greater geographical coverage.
• Grow through vertical integration thanks to the differential aspects of its value chain.
• Promote the creation of value through innovation.
• Consolidate its operational excellence.
• Evolve its teams and organizations for the future, with a special focus on attracting talent for key positions.
• Promote sustainability and risk management as main differentiators: climate change (carbon emissions, water consumption, etc.), as well as occupational, social, regulatory, political, reputational and industrial risks.

Enrique López, CFO of AMFRESH Group, highlights “The Bluestone equity transaction allows us to focus AMFRESH’s objectives in the best possible way, because the determined support of the Bluestone family holding will give us the opportunity to promote the investment projects that we already had in our portfolio, thus consolidating our model of sustained growth and providing it with greater agility. The Group’s performance gives us full confidence that we will achieve our objectives until 2028. We also have the support of our agricultural partners, retailer partners and the financial community at a global level.”

Media Contact

Patricia Sagarminaga

patricia.sagarminaga@amfresh.com

+ 34 669161941

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cc35d529-4be2-4e17-9cb4-215628229aa6

GlobeNewswire Distribution ID 8872954

LONDON, July 12, 2023 (GLOBE NEWSWIRE) — Webull Corporation (“Webull”), the owner of the popular Webull trading platform, today announced the launch of its retail brokerage services in the UK. Through licensed financial services trading firm Webull Securities (UK) Ltd. (“Webull UK”), a subsidiary of Webull, residents of the UK can now trade U.S.-listed equities and fractional shares, all at low commissions through the award-winning Webull app. The Webull platform also makes news, industry data, and educational materials available to provide investors with the tools needed to make informed investment decisions.

Anthony Denier, Webull US CEO responsible for operations in America and Europe, stated, “Our first step into Europe follows on the heels of successful launches over the past two years in Singapore, Australia, Japan, and Hong Kong. While each country has very different requirements and expectations, we believe there is great potential in the UK and look forward to rapidly expanding our product range to cater to our British clients. Webull’s trading platform has become very popular in the United States, Hong Kong, and Singapore, and we are confident that the powerful trading tools and simple mobile format will prove equally attractive in the UK. We are sure our new clients will enjoy tech and enjoy investing.”

Webull UK secured its authorisation from the FCA in October 2022. It has spent the last six months hiring a team with local experience to help the platform exceed British expectations. While its offering will initially be limited to U.S.-listed securities, Webull UK expects to expand this rapidly, opening new global investment opportunities for retail investors.

Nick Saunders, Chief Executive Officer of Webull UK, said, “The investment market has changed in the last 10 years. The British public is now actively seeking low-cost investment opportunities domestically and in markets outside the UK. Webull’s strength is in our global network and innovative mindset; we look at the right solution for our clients, and seek to build on the existing, sustainable foundations to give our customers the product they want. As a pure broker, our interests are aligned with our clients. We provide the tools to help them make informed, global investment decisions.”

The Webull trading platform launched in the United States in 2018 through its SEC-registered broker-dealer and FINRA member subsidiary. In 2021, Webull was the second most downloaded app among pure-play brokerages in the U.S., according to mobile and data analytics firm App Annie. Webull has received notable recognition in the financial industry. In 2022, we won the “Best Brokerage App” award at Benzinga’s Global Fintech Awards, highlighting our commitment to superior mobile trading. We were also honored as the “Best Options Trading Platform” at the Finder Stock Trading Platform Awards. In the Stockbrokers Annual Review 2023, we were recognized as the “Best in Class” for the investor community. These accolades showcase our dedication to providing innovative and exceptional services to our users.

The Webull trading platform can be downloaded through the Apple App Store and the Google Play Store.

For more information about Webull UK, please visit Webull UK’s website at https://www.webull-uk.com. For media inquiries, please contact pr@webull.com.

About Webull

Webull is a leading digital investment platform built on next-generation global infrastructure. Webull serves tens of millions of users from over 180 countries, providing retail investors with 24/7 access to financial markets worldwide. Users can put investment strategies to work by trading global stocks, ETFs, options, and fractional shares, through Webull’s trading platform, which is currently available in the United States, Hong Kong, Singapore, Australia, South Africa, and Japan.

GlobeNewswire Distribution ID 8871304

Rediscovering History: Exploring the Fascinating the Ancient Tea-Horse Road in Yunnan

KUNMING, China, July 12, 2023 (GLOBE NEWSWIRE) — Yunnan Innyo Co., Ltd. is excited to collaborate with @visityunnan and share a series of videos of the Ancient Tea-Horse Road in Yunnan, China. The videos feature charming villages, famous tea mountains, delicious local cuisine, and comfortable accommodations, making Yunnan’s Ancient Tea-Horse Road known worldwide.

The Ancient Tea-Horse Road is a time-honored trade route connecting Southwest China with Tibet and Central Asia, with rich cultural and historical importance. The well-crafted tourism video covers four captivating themes, capturing the essence of Yunnan’s Ancient Tea-Horse Road experience.

Mysterious Villages
This video series showcases ancient village architecture, local villagers’ customs, and various handicrafts in Yunnan. These videos offer a unique opportunity to experience Yunnan’s ancient villages while mesmerized by their awe-inspiring landscapes.

Six Great Tea Mountains
These videos explore the six tea mountains scattered along the Lancang River in Yunnan, where the finest teas are cultivated. Witness the complex process of tea production, from picking tea leaves to tasting the tea. The video highlights international travelers enjoying the unique flavors of Yunnan tea amidst lush green tea gardens.

Food and Scenery
Embark on a gastronomic journey along the Ancient Tea-Horse Road, savoring diverse Yunnan delicacies from different regions. The video showcases the local cuisines of various ethnic groups, such as grilled fish with lemongrass and boiled chicken with sour bamboo shoots. Scenes of ethnic minorities singing and dancing at banquets highlight the region’s cultural diversity.

Banshan Hotel
These videos showcase the Banshan Hotel’s beautiful surroundings, distinctive design, impeccable service, and serene ambiance. Experience comfort and luxury at the Banshan Hotel along the Ancient Tea-Horse Road, Indulging in the stories of the Ancient Tea-Horse Road while rejuvenating amidst nature’s beauty.

These captivating video series are being released on @visityunnan’s major media platforms. To stay updated and explore the Ancient Tea-Horse Road in-depth, visit the official TikTok account @visityunnan, the official Facebook account @GoYunnan.Official, and the official Youtube account @visityunnan21! Join us on this virtual journey to rediscover history and immerse yourself in Yunnan’s rich culture, breathtaking scenery, and warm hospitality.

Media Contact

Official Website: https://www.visityunnanchina.com/

Email: row.wang@beyondsummits.com

TikTok：https://www.tiktok.com/@visityunnan

GlobeNewswire Distribution ID 8872997